Cipla is currently trading at Rs. 1524.60, up by 3.40 points or 0.22% from its previous closing of Rs. 1521.20 on the BSE.
The scrip opened at Rs. 1523.35 and has touched a high and low of Rs. 1527.00 and Rs. 1513.75 respectively. So far 16662 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1310.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1536.20 and Rs. 1495.95 respectively. The current market cap of the company is Rs. 123294.16 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.79% and 16.00% respectively.
Cipla has completed acquisition of 100% stake in Inzpera Healthsciences (Inzpera) on December 04, 2025. Accordingly, Inzpera has now become a wholly owned subsidiary of the Company.
The acquisition is a strategic move aimed at combining Inzpera’s extensive portfolio of paediatric pharmaceutical and wellness products with the company’s strong distribution network and operational capabilities to drive growth and scalability. Earlier, the company had entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: